t
ImmuPharma PLC confirmed on 20 May 2025 that the Notice of Annual General Meeting (AGM) and the Annual Report and Accounts for the year ended 31 December 2024 were posted to shareholders. The company's AGM is scheduled for Thursday, 12 June 2025, at 11:00 am (BST) at The Malmaison Hotel, 18-21 Charterhouse Square, Barbican, London EC1M 6AH.
| Date | 20 May 2025 |
| Time | 07:00:12 |
| Category | AGMs and other meetings |
| ID | 1150J |
20 May 2025
ImmuPharma PLC
("ImmuPharma" or the "Company")
Notice of AGM & Annual Report & Accounts
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting ("AGM") has today been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2024 has also been posted to shareholders today.
These documents will be available shortly, in electronic form, for download on the Company's website www.immupharma.co.uk.
ImmuPharma's AGM will be held on Thursday 12th June 2025 @ 11:00am (BST) at: The Malmaison Hotel, 18-21 Charterhouse Square, Barbican, London EC1M 6AH.
Ends
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140, is a unique non-immunosuppressive peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895